PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.11%
Positive EBIT growth while CRON.TO is negative. John Neff might see a substantial edge in operational management.
24.11%
Positive operating income growth while CRON.TO is negative. John Neff might view this as a competitive edge in operations.
25.74%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
25.49%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
25.49%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-83.48%
Negative OCF growth while CRON.TO is at 234.45%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-83.48%
Negative FCF growth while CRON.TO is at 94.16%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.32%
AR growth well above CRON.TO's 23.99%. Michael Burry fears inflated revenue or higher default risk in the near future.
No Data
No Data available this quarter, please select a different quarter.
-1.39%
Negative asset growth while CRON.TO invests at 1.85%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.86%
Positive BV/share change while CRON.TO is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.11%
We cut SG&A while CRON.TO invests at 8.16%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.